Christina N. Kraus

Christina N. Kraus

Auto-generated profile, based on publicly available information

Christina N. Kraus

Department of Dermatology, University of California, Irvine, California

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2021 in International Journal of Women's Dermatology
Verified
Journal Article
Open access
SSSamantha Sattler
Samantha Sattler
AEAshley N. Elsensohn
Ashley N. Elsensohn
MMMelissa M. Mauskar
Melissa M. Mauskar
CKChristina N. Kraus
Christina N. Kraus
Plasma cell vulvitis (PCV) is an inflammatory vulvar dermatosis that is not well characterized. Diagnosis is often delayed, and the condition can be refractory to treatment. To date, there are no systematic reviews on this topic. This study aimed to provide a systematic review of PCV, including epidemiologic, clinical, and histopathologic findings, as well as associated comorbidities and treatment options. A primary literature search was conducted using the PubMed, Ovid Medline, Cochrane, and CINAHL databases. Fifty-three publications with 196 patients (mean age: 55.3 ± 14.5 years) were included. The majority of studies were case reports and case series. Common symptoms included burning/stinging (52%), dyspareunia (44%), and pruritus (41%). Common findings included erythema (84%), glistening/shiny appearance (29%), well-demarcated lesions (25%), and erosions (22%). Common anatomic sites were the labia minora (45%), introitus (31%), and periurethral (19%). Fifty-three percent of patients had a solitary lesion. Common histologic findings were a predominant plasma cell infiltrate (88%), presence of other inflammatory cells (55%), hemosiderin/siderophages (46%), and epidermal atrophy (43%). Topical corticosteroids (64%) and tacrolimus ointment (13%) were the most frequent treatment modalities. In most reports, previous treatments were tried, and there was a diagnostic delay. PCV is likely underrecognized and should be considered in patients with erythema of the mucous and modified mucous membranes, symptoms of burning or stinging, and a predominant plasma cell infiltrate on histopathology. First-line therapy should begin with high-potency topical corticosteroids, with the most evidence for clobetasol 0.05% or tacrolimus 0.1% ointment. Prospective studies are needed to further characterize this condition and to develop treatment guidelines.

29 August 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PSPeng Sun
Peng Sun
CKChristina N. Kraus
Christina N. Kraus
WZWei Zhao
Wei Zhao
JXJiahui Xu
Jiahui Xu
SSSusie Suh
Susie Suh
XDXing Dai
Xing Dai

1 January 2020 in Dermatologic Surgery
Verified
Journal Article
Closed access
SCSama K. Carley
Sama K. Carley
CKChristina N. Kraus
Christina N. Kraus
JCJoel L. Cohen
Joel L. Cohen
BACKGROUND: Dermal necrosis is a rare yet serious risk associated with cosmetic filler injections, and although current consensus recommends the use of hyaluronidase injections in cases of hyaluronic acid filler, the efficacy of topical nitroglycerin as a treatment has not yet been fully investigated. OBJECTIVE: To review the literature on tissue necrosis resulting from soft tissue augmentation and to highlight the use of topical nitroglycerin as a first-line treatment. METHODS: A review of the literature was performed with no time limitations resulting in 35 articles and 66 patients who experienced tissue necrosis secondary to injectable fillers. Articles were reviewed for pertinent information and presented. RESULTS: Only 7 of the 66 reported cases (10%) used topical nitroglycerin as a treatment. Six of 7 (85%) were successful in halting the impending necrosis. Fifty-nine patients received alternative treatments, with hyaluronidase injection being the most common. Few reports of novel treatments for necrosis included the use of topical growth factors and injection of adipose-derived stem cells. CONCLUSION: Topical nitroglycerin is a potentially effective and underused treatment for tissue necrosis from soft tissue augmentation, but because data are very limited, topical nitroglycerin should be used in conjunction with hyaluronidase injections in cases of hyaluronic acid filler dermal necrosis.

15 June 2023 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
IEIlhan Esse
Ilhan Esse
KRKathryn Hinchee Rodriguez
Kathryn Hinchee Rodriguez
AKAlexa Kassels
Alexa Kassels
JSJessica Shiu
Jessica Shiu
CKChristina N. Kraus
Christina N. Kraus

30 November 2022 in Dermatopathology
Verified
Journal Article
Open access
PDF file
APAriel Park
Ariel Park
LWLulu Wong
Lulu Wong
ALAnnalise Lang
Annalise Lang
CKChristina Kraus
Christina Kraus
NANancy Anderson
Nancy Anderson
Ashley ElsensohnAshley Elsensohn
Ashley Elsensohn
Dupilumab is a humanized IgG4 monoclonal-antibody that is approved by the United States Food and Drug Administration (FDA) for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older. In recent years, several case studies have associated the unmasking or progression of cutaneous T-cell lymphomas (CTCL) with dupilumab treatment. To date, all reported cases of dupilumab-associated CTCL have shown a CD4+ T-helper-cell-predominant immunophenotype. Here, we report a case of a 72-year-old man who presented with a 2-year history of a diffuse, pruritic eruption, who was started on dupilumab for 9 weeks. He subsequently developed mycosis fungoides (MF) with a CD8+-predominant immunophenotype. Overall, cases of CD8+ mycosis fungoides are less common and relatively less understood than their CD4+ counterparts, with varied presentations and courses. We present a case of dupilumab-associated CD8+ MF to highlight this presentation for pathologists and providers.

19 November 2023 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
AKAlexa Kassels
Alexa Kassels
AEAshley N. Elsensohn
Ashley N. Elsensohn
CKChristina N. Kraus
Christina N. Kraus